RayKnowChina Research Map
Shortlist

Xi'anXi'an Jiaotong University

First Affiliated Hospital of Xi'an Jiaotong University

西安交通大学第一附属医院

Listed for 24 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Xi'an Jiaotong University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌122 papers led1 open trial led
  4. Stomach cancer胃癌69 papers led1 open trial led
  5. Hepatoblastoma肝母细胞瘤0 papers led
  6. Retinoblastoma视网膜母细胞瘤4 papers led
  7. Osteosarcoma骨肉瘤2 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
  9. Neuroblastoma神经母细胞瘤3 papers led
  10. Ewing sarcoma尤文肉瘤0 papers led
  11. Multiple myeloma多发性骨髓瘤8 papers led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  13. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  14. Haemophilia A血友病 A1 paper led
  15. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  16. Takayasu arteritis大动脉炎2 papers led
  17. Hepatic echinococcosis肝包虫病0 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化8 papers led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  20. Fabry disease法布雷病0 papers led
  21. Behçet disease白塞病0 papers led
  22. IgA nephropathyIgA 肾病7 papers led
  23. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  24. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Chordoma, Aplastic anaemia, Beta thalassaemia, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Xi'an for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  2. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy technique
Departments in papersENT / head & neck surgeryMedical oncology

Over half of these papers are lab or animal studies.

Papers it led6
  1. Inhibition of MAC30 exerts antitumor effects in nasopharyngeal carcinoma via affecting the Akt/GSK-3β/β-catenin pathway.2022Journal of biochemical and molecular toxicology
  2. 2,5-dimethyl celecoxib induces apoptosis and autophagy via activation of ROS/JNK axis in nasopharyngeal carcinoma cells.2021AgingFree full text
  3. Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study.2021BMJ openFree full text
  4. Oridonin inhibits epithelial-mesenchymal transition of human nasopharyngeal carcinoma cells by negatively regulating AKT/STAT3 signaling pathway.2021International journal of medical sciencesFree full text
  5. FBP1 enhances the radiosensitivity by suppressing glycolysis via the FBXW7/mTOR axis in nasopharyngeal carcinoma cells.2021Life sciences
  6. RSPO2 silence inhibits tumorigenesis of nasopharyngeal carcinoma by ZNRF3/Hedgehog-Gli1 signal pathway.2021Life sciences
All its trials on ClinicalTrials.gov, any status2
  1. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  2. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
More papers found outside PubMed (not counted)18
  1. Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  2. Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  3. Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  4. Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  5. Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  6. Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  7. Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  8. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  9. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  10. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figsharedataset
  11. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  12. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  13. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  14. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  15. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  16. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  17. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  18. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
12
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 5520232024: 4420242025: 222025

5 hospitals in Xi'an for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07796113

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  2. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  3. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyMolecular markers & genomicsImaging & AI
Departments in papersRadiation oncologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led12
  1. Relaxin 2 Suppresses Tumor Growth in Esophageal Squamous Cell Carcinoma EC9706 Cells Through Modulation of the STAT Signaling Pathway.2025Journal of biochemical and molecular toxicology
  2. HPV16 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma by Promoting De Novo Fatty Acid Synthesis and Disulfidptosis.2025Journal of medical virology
  3. Circ_FNDC3B Promotes Cell Proliferation and Metastasis in Esophageal Squamous Cell Carcinoma via Regulating MAPK1 by Binding to miR-136-5p.2024Biochemical genetics
  4. Survival benefits of human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective cohort study.2024Journal of medical virology
  5. SP4 Facilitates Esophageal Squamous Cell Carcinoma Progression by Activating PHF14 Transcription and Wnt/Β-Catenin Signaling.2024Molecular cancer research : MCRFree full text
  6. Pristimerin exhibits anti-cancer activity by inducing ER stress and AKT/GSK3β pathway through increasing intracellular ROS production in human esophageal cancer cells.2024Toxicology in vitro : an international journal published in association with BIBRA
  7. The AEG-1-USP10-PARP1 axis confers radioresistance in esophageal squamous cell carcinoma via facilitating homologous recombination-dependent DNA damage repair.2023Cancer letters
  8. SPARC expression in tumor microenvironment induces partial epithelial-to-mesenchymal transition of esophageal adenocarcinoma cells via cooperating with TGF-β signaling.2023Cell biology international
  9. Identification of m5C-related lncRNAs signature to predict prognosis and therapeutic responses in esophageal squamous cell carcinoma patients.2023Scientific reportsFree full text
  10. An artificial neural network-based radiomics model for predicting the radiotherapy response of advanced esophageal squamous cell carcinoma patients: a multicenter study.2023Scientific reportsFree full text
  11. MiR-671-5p sponging activity of circMMP1 promotes esophageal squamous cancer progression.2023Thoracic cancerFree full text
  12. Radiation induces NORAD expression to promote ESCC radiotherapy resistance via EEPD1/ATR/Chk1 signalling and by inhibiting pri-miR-199a1 processing and the exosomal transfer of miR-199a-5p.2021Journal of experimental & clinical cancer research : CRFree full text
All its trials on ClinicalTrials.gov, any status7
  1. Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCRecruitingNCT07796113Lead sponsorPhase 2Start 2025-10
  2. Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)Status unknownNCT05603065Lead sponsorPhase 4Start 2022-10
  3. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  4. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
  5. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  6. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  7. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
More papers found outside PubMed (not counted)22
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. 931P Update results of tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study2025Annals of Oncologyarticle
  3. KDM6B Promotes the Development, Progression and Metastasis of Oesophageal Cancer through Demethylation of Histones in the LDHA Promoter Region2025Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agentsarticle
  4. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  5. Construction of eukaryotic expression vector of Apoptin-etag and TAT-Apoptin-etag and their effects on human esophageal squamous cell carcinoma in vitro2024Research Squarepreprint
  6. Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study.2024Journal of Clinical Oncologyconference-abstract
  7. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  8. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  9. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  10. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  11. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  12. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  13. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  14. Tumor marker index based on CYFRA21-1 and NSE is an important screening index for early-stage esophageal squamous cell carcinoma high-risk groups2023Research Squarepreprint
  15. Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p2022Figsharedataset
  16. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  17. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figsharedataset
  18. The oncogene EIF3c promotes esophageal squamous cell carcinoma tumorigenesis by inhibiting cell proliferation and inducing cell apoptosis2022Research Squarepreprint
  19. The oncogene EIF3c promotes esophageal squamous cell carcinoma tumorigenesis by inhibiting cell proliferation and inducing cell apoptosis2022Research Squarepreprint
  20. Comparative Study on the Esophageal Microflora of Different Tissue Types in Patients With Esophageal Squamous Cell Carcinoma2021Venue not listedpreprint
  21. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract
  22. Repair of tracheoesophageal fistula with pedicled sternocleidomastoid muscle flap after minimally invasive esophagectomy: A case report2021Journal of Clinical Images and Medical Case Reportsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 122 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
122
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 323220212022: 232320222023: 202020232024: 212120242025: 24242025

4 hospitals in Xi'an for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07079150

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  2. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  4. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led122
  1. p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma.2026Cell reports
  2. FOXP1-transcriptionally regulated AEG-1 enhances tumor cell stemness to promote hepatocellular carcinoma radioresistance.2026Molecular and cellular biochemistry
  3. Relationship between contrast-enhanced ultrasound combined with ultrasound resolution microscopy imaging and histological features of hepatocellular carcinoma.2025Abdominal radiology (New York)
  4. Dual-responsive magnetic vortex nanorings co-deliver lenvatinib and localized heat for synergistic activation of antitumor immunity.2025Acta biomaterialia
  5. Copper-Based Nanotubes That Enhance Starvation Therapy Through Cuproptosis for Synergistic Cancer Treatment.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. Perioperative Changes in Serum Transaminase Levels: Impact on Postoperative Morbidity After Liver Resection of Hepatocellular Carcinoma.2025Annals of surgery
  7. Perioperative Changes in Serum Transaminases Levels Predicts Long-Term Survival Following Liver Resection of Hepatocellular Carcinoma.2025Annals of surgical oncology
  8. A non-invasive nomogram for the prediction of poor prognosis of hepatocellular carcinoma based on the novel marker Interleukin-41.2025BMC cancerFree full text
  9. Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.2025BMC gastroenterologyFree full text
  10. WWOX-mediated p53/SAT1 and NRF2/FPN1 axis contribute to toosendanin-induced ferroptosis in hepatocellular carcinoma.2025Biochemical pharmacology
  11. A novel hypoxia-induced lncRNA, SZT2-AS1, boosts HCC progression by mediating HIF heterodimerization and histone trimethylation under a hypoxic microenvironment.2025Cell death and differentiationFree full text
  12. CCDC154 knockdown inhibits growth of liver cancer via suppressing expression of Snail.2025European journal of medical researchFree full text
  13. Perioperative dynamic changes of systemic inflammatory biomarkers predict tumor recurrence following curative-intent resection of hepatocellular carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  14. Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma.2025Experimental & molecular medicineFree full text
  15. Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.2025Frontiers in immunologyRCTFree full text
  16. A novel oncogene, leucine-rich repeat protein 1, mediates hypoxia-induced hepatocellular carcinoma progression.2025Functional & integrative genomics
  17. Sex disparity of liver cancer recurrence following surgery: sex-determining region Y gene promotes immunosuppressive microenvironment and favors metastasis.2025International journal of surgery (London, England)Free full text
  18. Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.2025Journal of gastroenterology
  19. Multi-omics profiling reveals downregulated tumor lysine metabolism reshaping the immune microenvironment and therapeutic responses in hepatocellular carcinoma.2025Journal of translational medicineFree full text
  20. Identification of matrix stiffness-related molecular subtypes in HCC via integrating multi-omics analysis and machine learning algorithms.2025Journal of translational medicineFree full text
  21. CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.2025Journal of translational medicineFree full text
  22. FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner.2025Molecular and cellular biochemistry
  23. High glucose facilitates hepatocellular carcinoma cell proliferation and invasion via WTAP-mediated HK2 mRNA stability.2025Molecular and cellular biochemistry
  24. A ROS-mediated oxidation-O-GlcNAcylation cascade governs ferroptosis.2025Nature cell biology
  25. C-Myc-activated FKBP4 promotes hepatocellular carcinoma cell proliferation and invasion by regulating the PHLPP1/AKT pathway.2025Pathology, research and practice
  26. Development of a MVI associated HCC prognostic model through single cell transcriptomic analysis and 101 machine learning algorithms.2025Scientific reportsFree full text
  27. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy.2024ACS applied materials & interfaces
  28. Intracellular Magnetic Hyperthermia Sensitizes Sorafenib to Orthotopic Hepatocellular Carcinoma Via Amplified Ferroptosis.2024ACS nano
  29. Bioinspired Tumor Calcification-Guided Early Diagnosis and Eradication of Hepatocellular Carcinoma.2024Advanced materials (Deerfield Beach, Fla.)
  30. Classification of Intrahepatic Cholangiocarcinoma into Perihilar Versus Peripheral Subtype.2024Annals of surgical oncology
  31. YAP1-activated ZNF131 promotes hepatocellular carcinoma cell proliferation through transcriptional regulation of PAIP1.2024Archives of biochemistry and biophysics
  32. Identification of pyroptosis-associated miRNAs in the immunoscape and prognosis of hepatocellular carcinoma.2024BMC cancerFree full text
  33. Establishment of nomogram prediction model of contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for vessels encapsulating tumor clusters pattern of hepatocellular carcinoma.2024Bioscience trends
  34. USP40 promotes hepatocellular carcinoma progression through a YAP/USP40 positive feedback loop.2024Cancer letters
  35. FOXP2 suppresses the proliferation, invasion, and aerobic glycolysis of hepatocellular carcinoma cells by regulating the KDM5A/FBP1 axis.2024Environmental toxicology
  36. Laparoscopic right upper transversal hepatectomy: Strategies for right hepatic vein resection and reconstruction.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  37. Preoperative and postoperative MRI-based models versus clinical staging systems for predicting early recurrence in hepatocellular carcinoma.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  38. The significance of m6A RNA methylation regulators in diagnosis and subtype classification of HBV-related hepatocellular carcinoma.2024Human cell
  39. DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA-sequencing.2024International immunopharmacology
  40. NDC1 promotes hepatocellular carcinoma tumorigenesis by targeting BCAP31 to activate PI3K/AKT signaling.2024Journal of biochemical and molecular toxicology
  41. Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma.2024Journal of colloid and interface science
  42. Effect of surface modification on the distribution of magnetic nanorings in hepatocellular carcinoma and immune cells.2024Journal of materials chemistry. B
  43. Self-assembled copper-based nanoparticles for enzyme catalysis-enhanced chemodynamic/photodynamic/antiangiogenic tritherapy against hepatocellular carcinoma.2024Journal of nanobiotechnology
  44. Platelet-derived microparticles adoptively transfer integrin β3 to promote antitumor effect of tumor-infiltrating T cells.2024OncoimmunologyFree full text
  45. TSC/mTORC1 mediates mTORC2/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M.2024The Journal of clinical investigationFree full text
  46. Three molecular subtypes and a five-gene signature for hepatocellular carcinoma based on m7G-related classification.2024The journal of gene medicine
  47. A Nomogram Based on Features of Ultrasonography and Contrast-Enhanced CT to Predict Vessels Encapsulating Tumor Clusters Pattern of Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  48. Reversal of HMGA1-Mediated Immunosuppression Synergizes with Immunogenic Magnetothermodynamic for Improved Hepatocellular Carcinoma Therapy.2023ACS nano
  49. METTL3-induced lncRNA GBAP1 promotes hepatocellular carcinoma progression by activating BMP/SMAD pathway.2023Biology directFree full text
  50. BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex.2023Cancer immunology, immunotherapy : CIIFree full text
  51. Advances in experimental animal models of hepatocellular carcinoma.2023Cancer medicineFree full text
  52. Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.2023Cell death & diseaseFree full text
  53. HIF-1α-activated TMEM237 promotes hepatocellular carcinoma progression via the NPHP1/Pyk2/ERK pathway.2023Cellular and molecular life sciences : CMLSFree full text
  54. Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma.2023Computers in biology and medicine
  55. The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis.2023Critical reviews in oncology/hematology
  56. HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells.2023Discovery medicine
  57. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report.2023Frontiers in immunologyFree full text
  58. miR-144-3p represses hepatocellular carcinoma progression by affecting cell aerobic glycolysis via FOXK1.2023International journal of experimental pathology
  59. A Cox Nomogram for Assessing Recurrence Free Survival in Hepatocellular Carcinoma Following Surgical Resection Using Dynamic Contrast-Enhanced MRI Radiomics.2023Journal of magnetic resonance imaging : JMRI
  60. Development and Validation of an α-Fetoprotein Tumor Burden Score Model to Predict Postrecurrence Survival among Patients with Hepatocellular Carcinoma.2023Journal of the American College of Surgeons
  61. Extracellular Vesicles in Hepatocellular Carcinoma: Progress and Challenges in the Translation from the Laboratory to Clinic.2023Medicina (Kaunas, Lithuania)Free full text
  62. Clinical significance of FBXO43 in hepatocellular carcinoma and its impact on tumor cell proliferation, migration and invasion.2023PeerJFree full text
  63. Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis.2023Scientific reportsFree full text
  64. Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular Carcinoma.2023Scientific reportsFree full text
  65. A Bayesian Network Prediction Model for Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma: A Multi-institutional Study.2023World journal of surgery
  66. Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy.2023World journal of surgical oncologyFree full text
  67. Hypoxia-induced lncRNA MRVI1-AS1 accelerates hepatocellular carcinoma progression by recruiting RNA-binding protein CELF2 to stabilize SKA1 mRNA.2023World journal of surgical oncologyFree full text
  68. Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma.2022Acta biochimica et biophysica SinicaFree full text
  69. ASO Author Reflections: Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma.2022Annals of surgical oncology
  70. Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma.2022Annals of surgical oncology
  71. AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy.2022Anti-cancer agents in medicinal chemistry
  72. HCG15 is a hypoxia-responsive lncRNA and facilitates hepatocellular carcinoma cell proliferation and invasion by enhancing ZNF641 transcription.2022Biochemical and biophysical research communications
  73. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.2022British journal of cancerFree full text
  74. LncRNA SNHG5 promotes the proliferation and cancer stem cell-like properties of HCC by regulating UPF1 and Wnt-signaling pathway.2022Cancer gene therapyFree full text
  75. Ubiquitin-specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma.2022Cancer scienceFree full text
  76. Identification of hepatocellular carcinoma subtypes based on PcG-related genes and biological relevance with cancer cells.2022Clinical epigeneticsFree full text
  77. Long Noncoding RNA BCYRN1 Recruits BATF to Promote TM4SF1 Upregulation and Enhance HCC Cell Proliferation and Invasion.2022Disease markersFree full text
  78. Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma.2022Disease markersFree full text
  79. MicroRNA-455-3p functions as a tumor suppressor by targeting HDAC2 to regulate cell cycle in hepatocellular carcinoma.2022Environmental toxicology
  80. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  81. Utilization of elderly donors in liver transplantation for patients with hepatocellular carcinoma: A national retrospective cohort study of China.2022International journal of surgery (London, England)
  82. Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma.2022Journal of colloid and interface science
  83. Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma.2022Journal of gastroenterology and hepatology
  84. Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  85. Integrating bulk and single-cell RNA sequencing reveals cellular heterogeneity and immune infiltration in hepatocellular carcinoma.2022Molecular oncologyFree full text
  86. Hypoxia-driven miR-1307-3p promotes hepatocellular carcinoma cell proliferation and invasion by modulating DAB2 interacting protein.2022Pathology, research and practice
  87. Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma.2022Scientific reportsFree full text
  88. Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.2022Seminars in liver diseaseFree full text
  89. The HN1/HMGB1 axis promotes the proliferation and metastasis of hepatocellular carcinoma and attenuates the chemosensitivity to oxaliplatin.2022The FEBS journal
  90. TRIM62 silencing represses the proliferation and invasion and increases the chemosensitivity of hepatocellular carcinoma cells by affecting the NF-κB pathway.2022Toxicology and applied pharmacology
  91. The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma.2021Abdominal radiology (New York)
  92. Novel role of LINC01013/miR-6795-5p/FMNL3 axis in the regulation of hepatocellular carcinoma stem cell features.2021Acta biochimica et biophysica Sinica
  93. ASO Author Reflections: Multi-institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma.2021Annals of surgical oncology
  94. Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma.2021Annals of surgical oncology
  95. Tumor Necrosis Impacts Prognosis of Patients Undergoing Curative-Intent Hepatocellular Carcinoma.2021Annals of surgical oncology
  96. ASO Author Reflections: Hepatocellular Carcinoma-Related Tumor Necrosis is Associated with Worse Long-Term Outcomes.2021Annals of surgical oncology
  97. Linc01559 Served as a Potential Oncogene and Promoted Resistance of Hepatocellular Carcinoma to Oxaliplatin by Directly Sponging miR-6783-3p.2021Anti-cancer agents in medicinal chemistry
  98. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.2021BMC cancerFree full text
  99. Prognosis of liver transplantation: Does postoperative ileus matter?2021BMC gastroenterologyFree full text
  100. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.2021Cancer letters
  101. HIF-1α-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway.2021Cell death & diseaseFree full text
  102. Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression.2021Cell death & diseaseFree full text
  103. Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation.2021Cellular signalling
  104. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma.2021Chinese medical journalFree full text
  105. A novel signature based on pairwise PD-1/PD-L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma.2021Clinical and translational medicineFree full text
  106. Hypoxia-induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway.2021Clinical and translational medicineFree full text
  107. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  108. HIPK3 Circular RNA Promotes Metastases of HCC Through Sponging miR-338-3p to Induce ZEB2 Expression.2021Digestive diseases and sciences
  109. Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  110. Hepatocellular-cholangiocarcinoma with sarcomatous change: Clinicopathological features and outcomes.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  111. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.2021International journal of medical sciencesFree full text
  112. Saikosaponin-d increases radiation-induced apoptosis of hepatoma cells by promoting autophagy via inhibiting mTOR phosphorylation.2021International journal of medical sciencesFree full text
  113. Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma.2021Journal of clinical laboratory analysisFree full text
  114. Long non-coding RNA MAPKAPK5-AS1/PLAGL2/HIF-1α signaling loop promotes hepatocellular carcinoma progression.2021Journal of experimental & clinical cancer research : CRFree full text
  115. Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  116. A study on the inconsistency of arterial phase hypervascularity detection between contrast-enhanced ultrasound using sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid magnetic resonance imaging of hepatocellular carc2021Journal of medical ultrasonics (2001)
  117. Long noncoding RNA highly upregulated in liver cancer promotes the progression of hepatocellular carcinoma and attenuates the chemosensitivity of oxaliplatin by regulating miR-383-5p/vesicle-associated membrane protein-2 axis.2021Pharmacology research & perspectivesFree full text
  118. Biological features, gene expression profile, and mechanisms of drug resistance of two- and three-dimensional hepatocellular carcinoma cell cultures.2021Pharmacology research & perspectivesFree full text
  119. Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.2021PloS oneFree full text
  120. NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.2021Technology in cancer research & treatmentFree full text
  121. Evaluation of the Efficacy and Toxicity of Radiotherapy for Type III-IV Portal Vein Tumor Thrombi.2021Technology in cancer research & treatmentFree full text
  122. Cellular senescence in hepatocellular carcinoma induced by a long non-coding RNA-encoded peptide PINT87aa by blocking FOXM1-mediated PHB2.2021TheranosticsFree full text
Chinese-language papers (not in the count)5
  1. [Angio-associated migratory cell protein is highly expressed in hepatocellular carcinoma and promotes tumor cell invasion and metastasis].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [Overexpression of miR-607 inhibits hepatocellular carcinoma cell growth and metastasis by down-regulating TRPC5].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  3. [Regulatory effect of small nuclear ribonucleoprotein-associated protein B on proliferation and metastasis of liver cancer cells].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Regulatory effects of LIM kinase 1 on the proliferation and metastasis of hepatocellular carcinoma cells].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status28
  1. Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort StudyRecruitingNCT07079150Lead sponsorStart 2025-01
  2. Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib TreatmentStatus unknownNCT05113290Lead sponsorPhase 4Start 2021-12
  3. Camrelizumab Utilization on Patients With Advanced Liver CancerStatus unknownNCT04487704Lead sponsorN/AStart 2020-04
  4. Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery RecurrenceStatus unknownNCT04213118Lead sponsorPhase 2Start 2020-04
  5. ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver CancerStatus unknownNCT03965546Lead sponsorEarly phase 1Start 2019-05
  6. ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular CarcinomaCompletedNCT03888859Lead sponsorEarly phase 1Start 2017-12
  7. Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver TransplantationCompletedNCT07418138Lead (inferred)Start 2015-01
  8. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  9. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  10. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  11. Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung CancerSuspendedNCT06653023Study siteEarly phase 1Start 2024-10
  12. A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250Study siteStart 2024-07
  13. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  14. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Study sitePhase 2Start 2021-03
  15. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  16. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  17. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Study sitePhase 2Start 2020-09
  18. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  19. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  20. Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan CriteriaStatus unknownNCT03469479Study sitePhase 3Start 2018-03
  21. HAIC of FOLFOX vs. HAIC of OXA for Advanced HCCStatus unknownNCT03468231Study sitePhase 3Start 2018-03
  22. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  23. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  24. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  25. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  26. HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCCCompletedNCT02856126Study sitePhase 3Start 2016-08
  27. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11
  28. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Study sitePhase 2/Phase 3Start 2003-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 69 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.7%.

Papers led
69
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 191920212022: 222220222023: 7720232024: 111120242025: 10102025

5 hospitals in Xi'an for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
    Phase
    Phase 4
    Started
    2024-07
    Registry
    NCT06499610

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  2. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  3. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  4. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  5. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  6. Recruiting
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07029269

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an

  7. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  8. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopySurgeryPeritoneal spread & advanced disease
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyRadiology / nuclear medicine
Papers it led69
  1. The mediating role of postoperative blood glucose in the relationship between body composition and overall survival in non-diabetic gastric cancer patients.2025BMC cancerFree full text
  2. Analyses of single-cell RNA sequencing uncover the role of intratumoral Helicobacter pylori in shaping tumor progression and immunity in gastric cancer.2025Cancer immunology, immunotherapy : CIIFree full text
  3. A multi-omics prognostic model of cuproptosis affects the prognosis of stomach adenocarcinoma.2025Clinical epigeneticsFree full text
  4. USP26 Promotes Cell Proliferation of Gastric Cancer by Stabilizing c-Myc.2025DNA and cell biology
  5. Investigation of the gastric toxicity induced by exposure to tri-isobutyl phosphate.2025Ecotoxicology and environmental safety
  6. Preoperative Glycosylated Hemoglobin A1C Impacts Long-Term Outcomes Following Curative-Intent Resection of Nonfunctional Gastroenteropancreatic Neuroendocrine Tumors.2025Journal of surgical oncologyFree full text
  7. Construction and effect evaluation of perioperative nursing model for gastric cancer patients based on enhanced recovery after surgery (ERAS) concept.2025MedicineFree full text
  8. A fully annotated pathology slide dataset for early gastric cancer and precancerous lesions.2025Scientific dataFree full text
  9. Clinical outcomes and cost-effectiveness analysis of robotic and endoscopic cooperative surgery for treating gastric submucosal tumors: a longitudinal nested cohort study.2025Surgical endoscopyFree full text
  10. Quantifying Tumor Budding: Implications for Prognosis in Gastric Adenocarcinoma.2025The American journal of surgical pathology
  11. The spatiotemporal associations between esophageal and gastric cancers provide evidence for its joint endoscopic screening in China: a population-based study.2024BMC medicineFree full text
  12. Gastric cancer patient-derived organoids model for the therapeutic drug screening.2024Biochimica et biophysica acta. General subjects
  13. Single-cell RNA sequencing to map tumor heterogeneity in gastric carcinogenesis paving roads to individualized therapy.2024Cancer immunology, immunotherapy : CIIFree full text
  14. Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination.2024European journal of pharmacology
  15. Xenograft and organoid models in developing precision medicine for gastric cancer (Review).2024International journal of oncologyFree full text
  16. Efficacy, safety, and advantages of magnetic anchor-guided endoscopic submucosal dissection vs conventional endoscopic submucosal dissection: A retrospective paired cohort study.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  17. Preoperative anemia: impact on short- and long-term outcomes following curative-intent resection of gastroenteropancreatic neuroendocrine tumors.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  18. miR-181-5p/KLHL5 Promoted Proliferation and Migration of Gastric Cancer Through Activating METTL3-Mediated m6A Process.2024Molecular biotechnology
  19. Preparation and identification of a fluorescent probe with CsPbBr3perovskite quantum dots and CD44v6 specific peptide for gastric cancer imaging.2024Nanotechnology
  20. Identification of miRNA, lncRNA and circRNA associated with gastric cancer metabolism through sequencing and bioinformatics analysis.2024Pathology, research and practice
  21. Expression patterns of E2Fs identify tumor microenvironment features in human gastric cancer.2024PeerJFree full text
  22. The clinicopathological characteristics of gastric cancer and precancerous conditions in gastric DLBCL and MALT lymphoma patients: a multi-center retrospective study.2023Annals of medicineFree full text
  23. CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series.2023BMC medical imagingFree full text
  24. USP14-mediated deubiquitination of SIRT1 in macrophage promotes fatty acid oxidation amplification and M2 phenotype polarization.2023Biochemical and biophysical research communications
  25. Study on TFF1 and PALB2 gene variants associated with gastric carcinoma risk in the Chinese Han population.2023Cancer epidemiology
  26. The factors influencing the accuracy of pre-operative endoscopic ultrasonography assessment in endoscopic treatments for gastrointestinal tumors.2023Cancer medicineFree full text
  27. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways.2023Experimental & molecular medicineFree full text
  28. The comparison of long-term oncological outcomes and complications after proximal gastrectomy with double tract reconstruction versus total gastrectomy for proximal gastric cancer.2023World journal of surgical oncologyFree full text
  29. Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection.2022BMC cancerFree full text
  30. A novel 450-nm laser-mediated sinoporphyrin sodium-based photodynamic therapy induces autophagic cell death in gastric cancer through regulation of the ROS/PI3K/Akt/mTOR signaling pathway.2022BMC medicineFree full text
  31. The nuclear-localized GHR is involved in the cell proliferation of gastric cancer, and pegvisomant may be an important potential drug to inhibit the proliferation of gastric cancer cells.2022Biochemistry and cell biology = Biochimie et biologie cellulaire
  32. Collagen type IV alpha 1 (COL4A1) silence hampers the invasion, migration and epithelial-mesenchymal transition (EMT) of gastric cancer cells through blocking Hedgehog signaling pathway.2022BioengineeredFree full text
  33. Comprehensive Analysis of Alternative Splicing in Gastric Cancer Identifies Epithelial-Mesenchymal Transition Subtypes Associated with Survival.2022Cancer researchFree full text
  34. Inhibition of MDFI attenuates proliferation and glycolysis of Helicobacter pylori-infected gastric cancer cells by inhibiting Wnt/β-catenin pathway.2022Cell biology international
  35. Integration of exosomal miR-106a and mesothelial cells facilitates gastric cancer peritoneal dissemination.2022Cellular signalling
  36. Effect of Self-Transcendence Theory Combined with Comprehensive Nursing Intervention under Tumor Nutrition Education on Symptom Improvement, Nutritional Status, and Positive Psychology of Elderly Patients with Gastric Cancer.2022Contrast media & molecular imagingFree full text
  37. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  38. CircRNA-ABCB10 promotes gastric cancer progression by sponging miR-1915-3p to upregulate RaC1.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  39. Inhibition of Ras protein activator like 2 produces antitumor effects in gastric cancer via the suppression of YAP1 activation.2022Environmental toxicology
  40. Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma.2022Frontiers in immunologyFree full text
  41. Analysis of immune status in gastric adenocarcinoma with different infiltrating patterns and origin sites.2022Frontiers in immunologyFree full text
  42. The genetic polymorphisms in the SP4 gene and the risk of gastric cancer.2022Future oncology (London, England)
  43. SERPINA5 promotes tumour cell proliferation by modulating the PI3K/AKT/mTOR signalling pathway in gastric cancer.2022Journal of cellular and molecular medicineFree full text
  44. Diagnostic value of carcinoembryonic antigen combined with cytokines in serum of patients with colorectal cancer.2022MedicineFree full text
  45. Efficacy and safety of laparoscopic distal D2 radical gastrectomy for advanced gastric cancer patients.2022Minerva gastroenterology
  46. High level of TXNDC9 predicts poor prognosis and contributes to the NF-κB-regulated metastatic potential in gastric cancer.2022Neoplasma
  47. Deubiquitinase USP13 promotes the epithelial-mesenchymal transition and metastasis in gastric cancer by maintaining Snail protein.2022Pathology, research and practice
  48. Endoscopic submucosal dissection treatment of metachronous early gastric adenocarcinoma in a case with diffuse large B-cell lymphoma.2022Revista espanola de enfermedades digestivas
  49. Predictive value of neutrophil-to-lymphocyte ratio for distant metastasis in gastric cancer patients.2022Scientific reportsFree full text
  50. Clinical outcomes and functional analysis of third space robotic and endoscopic cooperative surgery versus laparoscopic wedge resection for gastric submucosal tumours: a propensity score-matched study.2022Updates in surgeryFree full text
  51. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.2021BMC cancerFree full text
  52. A high level of lncFGD5-AS1 inhibits epithelial-to-Mesenchymal transition by regulating the miR-196a-5p/SMAD6/BMP axis in gastric Cancer.2021BMC cancerFree full text
  53. Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8+ T cell cytotoxicity in patients with gastric cancer.2021BMC immunologyFree full text
  54. The circACC1/miR-29c-3p/FOXP1 network plays a key role in gastric cancer by regulating cell proliferation.2021Biochemical and biophysical research communications
  55. miR-4677-3p participates proliferation and metastases of gastric cancer cell via CEMIP-PI3K/AKT signaling pathway.2021Cell cycle (Georgetown, Tex.)Free full text
  56. Oxidative stress activates NORAD expression by H3K27ac and promotes oxaliplatin resistance in gastric cancer by enhancing autophagy flux via targeting the miR-433-3p.2021Cell death & diseaseFree full text
  57. A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  58. Flap endonuclease 1 (FEN1) as a novel diagnostic and prognostic biomarker for gastric cancer.2021Clinics and research in hepatology and gastroenterology
  59. Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2.2021Critical reviews in eukaryotic gene expression
  60. LINC01436 Inhibited miR-585-3p Expression and Upregulated MAPK1 Expression to Promote Gastric Cancer Progression.2021Digestive diseases and sciences
  61. Knockdown of DDX46 suppresses the proliferation and invasion of gastric cancer through inactivating Akt/GSK-3β/β-catenin pathway.2021Experimental cell research
  62. Deubiquitinase PSMD7 promotes the proliferation, invasion, and cisplatin resistance of gastric cancer cells by stabilizing RAD23B.2021International journal of biological sciencesFree full text
  63. Long non-coding RNA MSC-AS1 facilitates the proliferation and glycolysis of gastric cancer cells by regulating PFKFB3 expression.2021International journal of medical sciencesFree full text
  64. Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression.2021Journal of translational medicineFree full text
  65. Intraoperative localization of gastrointestinal tumors by magnetic tracer technique during laparoscopic-assisted surgery (with video).2021Scandinavian journal of gastroenterology
  66. A new endoscopic technique for specific gastrointestinal stromal tumors: a retrospective cohort study.2021Scandinavian journal of gastroenterology
  67. LINC00963/miR-4458 regulates the effect of oxaliplatin in gastric cancer by mediating autophagic flux through targeting of ATG16L1.2021Scientific reportsFree full text
  68. A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer.2021Scientific reportsFree full text
  69. Value of preoperative gastroscopic carbon nanoparticles labeling in patients undergoing laparoscopic radical gastric cancer surgery.2021Surgical oncology
Chinese-language papers (not in the count)2
  1. [Influence of visceral lipids obesity on the early postoperative complications after radical gastrectomy].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Efficacy of laparoscopic proximal gastrectomy with double-tract reconstruction versus laparoscopic total gastrectomy with Roux-en-Y reconstruction for early upper gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status35
  1. Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric CancerNot yet recruitingNCT06499610Lead sponsorPhase 4Start 2024-07
  2. Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric CancerStatus unknownNCT04792515Lead sponsorPhase 2Start 2021-01
  3. Comparison of the Efficiency Between Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy With Docetaxel Combine Oxaliplatin in Patients With Advanced Gastric CancerStatus unknownNCT04522011Lead sponsorStart 2021-01
  4. Effectiveness of Managing Suspected Metastasis and Progress Using Plasma D-dimer Testing in Gastric Cancer PatientsCompletedNCT04953585Lead sponsorStart 2019-01
  5. A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal AdenocarcinomaTerminatedNCT03890198Lead sponsorEarly phase 1Start 2019-04
  6. A New Method: the Third Space Robotic and Endoscopic Cooperative Surgery (TS-RECS)CompletedNCT03804762Lead sponsorN/AStart 2018-04
  7. Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal TumorsStatus unknownNCT03601234Lead sponsorN/AStart 2018-04
  8. Comparison of Open Laparoscopic and Robotic Surgery in Gastric Cancer Resection.Status unknownNCT03447106Lead sponsorN/AStart 2018-02
  9. A Randomized Controlled Clinical Study on the Application of the Third Space in the Operation of Gastric Submucosal TumorStatus unknownNCT03612830Lead sponsorN/AStart 2018-04
  10. Learning Curve for Robot-Assisted Gastrectomy in Gastric CancerStatus unknownNCT03940417Lead sponsorStart 2017-10
  11. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  12. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  13. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  14. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  15. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric CancerRecruitingNCT07029269Study sitePhase 3Start 2025-06
  16. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  17. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  18. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  19. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  20. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  21. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  22. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  23. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  24. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  25. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  26. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Study sitePhase 1Start 2020-07
  27. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  28. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  29. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  30. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  31. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  32. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  33. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  34. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  35. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total GastrectomyStatus unknownNCT02110628Study sitePhase 3Start 2014-08

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Xi'an for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Comprehensive analysis and experimental verification of LINC01314 as a tumor suppressor in hepatoblastoma.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 4 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.3%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 112025

9 hospitals in Xi'an for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

11 hospitals in Xi'an for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

3 hospitals in Xi'an for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led3
  1. CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series.2023BMC medical imagingFree full text
  2. Clinical outcomes and functional analysis of third space robotic and endoscopic cooperative surgery versus laparoscopic wedge resection for gastric submucosal tumours: a propensity score-matched study.2022Updates in surgeryFree full text
  3. A new endoscopic technique for specific gastrointestinal stromal tumors: a retrospective cohort study.2021Scandinavian journal of gastroenterology
Earlier papers (2016–2020)5
  1. Clinical feasibility and safety of third space robotic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumors dissection : A new surgical technique for treating gastric GISTs.2019Surgical endoscopy
  2. Clinicopathological and Prognostic Significance of Expression of B-Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (BMI-1) Gene and Protein in Gastrointestinal Stromal Tumors.2018Medical science monitor : international medical journal of experimental and clinical research
  3. Gastrointestinal stromal tumors: Fibrinogen levels are associated with prognosis of patients as blood-based biomarker.2018Medicine
  4. Prognostic value of fibrinogen and D-dimer-fibrinogen ratio in resectable gastrointestinal stromal tumors.2018World journal of gastroenterology
  5. Laparoscopic Versus Open Resection of Gastric Gastrointestinal Stromal Tumors Larger Than 5 cm: A Single-Center, Retrospective Study.2017Surgical innovation
All its trials on ClinicalTrials.gov, any status2
  1. Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal TumorsStatus unknownNCT03601234Lead sponsorN/AStart 2018-04
  2. the Laparoscopic and Endoscopic Cooperative Surgery of Gastrointestinal Stromal TumorStatus unknownNCT02763748Lead sponsorN/AStart 2016-06

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

12 hospitals in Xi'an for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Xi'an for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 8 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.5%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 1120242025: 222025

4 hospitals in Xi'an for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  2. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  3. Recruiting
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2021-02
    Registry
    NCT04634552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an

  4. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

  5. Not yet recruiting
    A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07090954

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskStem cell transplantCAR-T & cell therapy
Departments in papersNephrology
Papers it led8
  1. Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes.2025Current oncology (Toronto, Ont.)Free full text
  2. Deciphering N-Glycosylation Dynamics of Serum Monoclonal Immunoglobulins in Multiple Myeloma via EThcD-sceHCD-MS/MS.2025Journal of proteome research
  3. Exploring natural killer cell-related biomarkers in multiple myeloma: a novel nature killer cell-related model predicting prognosis and immunotherapy response using single-cell study.2024Clinical and experimental medicineFree full text
  4. Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma.2022BiomoleculesFree full text
  5. The effect of marital status on the survival of patients with multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  6. Cold Atmospheric Plasma Suppressed MM In Vivo Engraftment by Increasing ROS and Inhibiting the Notch Signaling Pathway.2022Molecules (Basel, Switzerland)Free full text
  7. Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.2021Frontiers in immunologyFree full text
  8. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.2021Hematology (Amsterdam, Netherlands)
Chinese-language papers (not in the count)1
  1. [A Retrospective Clinical Analysis of Multiple Myeloma Patients with Cardiac Amyloidosis].2025Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status7
  1. The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based MetabolomicsStatus unknownNCT05718401Lead sponsorStart 2022-11
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  3. A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple MyelomaNot yet recruitingNCT07090954Study sitePhase 1/Phase 2Start 2025-08
  4. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  5. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  6. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Study sitePhase 2Start 2021-02
  7. Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple MyelomaSuspendedNCT06663046Study siteEarly phase 1Start 2025-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Xi'an for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Ponsegromab in People With Heart FailureTerminatedNCT05492500Study sitePhase 2Start 2022-09
  2. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Xi'an for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & prognosisChildren

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Xi'an for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Xi'an for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.2016International journal of environmental research and public health

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Xi'an for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Xi'an for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 8 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 332025

10 hospitals in Xi'an for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Xi'an for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led3
  1. Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis.2023Human molecular genetics
  2. Comparative assessment of blood Metal/metalloid levels, clinical heterogeneity, and disease severity in amyotrophic lateral sclerosis patients.2022Neurotoxicology
  3. Characteristics of serum metabolites in sporadic amyotrophic lateral sclerosis patients based on gas chromatography-mass spectrometry.2021Scientific reports
Earlier papers (2016–2020)9
  1. Causal effects of serum metabolites on amyotrophic lateral sclerosis: A Mendelian randomization study.2020Progress in neuro-psychopharmacology & biological psychiatry
  2. Dominant Heterogeneity of Upper and Lower Motor Neuron Degeneration to Motor Manifestation of Involved Region in Amyotrophic Lateral Sclerosis.2019Scientific reports
  3. Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis and its differential diagnosis value.2019Scientific reports
  4. Decremental Responses to Repetitive Nerve Stimulation in Amyotrophic Lateral Sclerosis.2018European neurology
  5. Measuring the validation of assessing the non-dominant-hand function by ALSFRS-r in Chinese ALS patients.2017Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  6. Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort.2017Scientific reports
  7. Spread Direction and Prognostic Factors in Limb-Onset Sporadic Amyotrophic Lateral Sclerosis.2016European neurology
  8. Sympathetic Skin Response in Amyotrophic Lateral Sclerosis.2016Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  9. Hyperintensity of the corticospinal tract on FLAIR: A simple and sensitive objective upper motor neuron degeneration marker in clinically verified amyotrophic lateral sclerosis.2016Journal of the neurological sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Xi'an for Fabry disease80 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Xi'an for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Neuro-Behçet's syndrome with a severe ocular lesion.2019The Journal of international medical research

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 2220242025: 112025

7 hospitals in Xi'an for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led7
  1. Exploring the mediating role of immune cells in the pathogenesis of IgA nephropathy through the inflammatory axis of gut microbiota from a genomic perspective.2025Mammalian genome : official journal of the International Mammalian Genome Society
  2. Humoral immune responses primed by the alteration of gut microbiota were associated with galactose-deficient IgA1 production in IgA nephropathy.2024Frontiers in immunology
  3. Serum Phosphorus Might Be a Predictor of Kidney Disease Progression in IgA Nephropathy.2024Kidney & blood pressure research
  4. Spectrum of biopsy-proven kidney diseases in northwest China: a review of 30 years of experiences.2022International urology and nephrology
  5. Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy.2022Journal of the American Society of Nephrology : JASN
  6. Epidemiological characteristics and pathological changes of primary glomerular diseases.2022PloS one
  7. Renal deposition and clearance of recombinant poly-IgA complexes in a model of IgA nephropathy.2021The Journal of pathology
Earlier papers (2016–2020)3
  1. Association between the ACYP2 Polymorphisms and IgAN Risk in the Chinese Han Population.2019Kidney & blood pressure research
  2. Pregnancy-induced complications in IgA nephropathy: A case report.2018Medicine
  3. IgA nephropathy with leucocytoclastic vasculitis.2018The Journal of international medical research
All its trials on ClinicalTrials.gov, any status5
  1. SodiUm Restriction by Behavioral InterventionStatus unknownNCT04805047Lead sponsorN/AStart 2021-05
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  3. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  4. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  5. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Xi'an for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led2
  1. QTc interval prolongation in the patients with primary biliary cholangitis.2022Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
  2. MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-β1/smad Pathway.2021Journal of immunology research
All its trials on ClinicalTrials.gov, any status2
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Xi'an for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

西安交通大学第一附属医院

First Affiliated Hospital of Xi'an Jiaotong University

西安

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First Affiliated Hospital of Xi'an Jiao Tong University; he First Affiliated Hospital of Xi'an Jiaotong University; First Affiliated Hospital of Xian Jiao Tong University; First Affiliated Hospital of Xi'an JiaoTong University; First Affiliated Hospital of Xian Jiaotong University

Suggest a correctionDownload the data